Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study

Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the cont...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neurology Vol. 14; p. 1133390
Main Authors Baricich, Alessio, Battaglia, Marco, Cuneo, Daria, Cosenza, Lucia, Millevolte, Marzia, Cosma, Michela, Filippetti, Mirko, Dalise, Stefania, Azzollini, Valentina, Chisari, Carmelo, Spina, Stefania, Cinone, Nicoletta, Scotti, Lorenza, Invernizzi, Marco, Paolucci, Stefano, Picelli, Alessandro, Santamato, Andrea
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.04.2023
Subjects
botulinum toxin
movement disorders
multiple sclerosis
Neurology
pain
spasticity
spinal cord injury
botulinum toxin
spinal cord injury
pain
rehabilitation
multiple sclerosis
traumatic brain injury
spasticity
movement disorders
Online AccessGet full text

Cover

Abstract Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs. NCT04673240.
AbstractList Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs.
Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs. NCT04673240.
Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs. Clinical trial identifier NCT04673240.
Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs.Clinical trial identifierNCT04673240.
Author Millevolte, Marzia
Santamato, Andrea
Picelli, Alessandro
Chisari, Carmelo
Invernizzi, Marco
Cinone, Nicoletta
Baricich, Alessio
Battaglia, Marco
Cosenza, Lucia
Azzollini, Valentina
Spina, Stefania
Filippetti, Mirko
Dalise, Stefania
Scotti, Lorenza
Paolucci, Stefano
Cosma, Michela
Cuneo, Daria
AuthorAffiliation 1 Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale , Novara , Italy
7 Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona , Verona , Italy
6 Neuroscience and Rehabilitation Department, Ferrara University Hospital , Ferrara , Italy
4 Rehabilitation Unit, Department of Rehabilitation, “Santi Antonio e Biagio e Cesare Arrigo” National Hospital , Alessandria , Italy
10 Department of Translational Medicine, Unit of Medical Statistics, Università del Piemonte Orientale , Novara , Italy
5 Neurorehabilitation Clinic, Department Neurological Sciences, University Hospital of Ancona , Ancona , Italy
8 Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa , Pisa , Italy
11 Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, “Santi Antonio e Biagio e Cesare Arrigo” National Hospital , Alessandria , Italy
2 Phys
AuthorAffiliation_xml – name: 10 Department of Translational Medicine, Unit of Medical Statistics, Università del Piemonte Orientale , Novara , Italy
– name: 7 Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona , Verona , Italy
– name: 6 Neuroscience and Rehabilitation Department, Ferrara University Hospital , Ferrara , Italy
– name: 8 Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa , Pisa , Italy
– name: 5 Neurorehabilitation Clinic, Department Neurological Sciences, University Hospital of Ancona , Ancona , Italy
– name: 12 IRCCS Fondazione Santa Lucia , Rome , Italy
– name: 2 Physical and Rehabilitation Medicine, “Ospedale Maggiore della Carità” University Hospital , Novara , Italy
– name: 9 Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia , Foggia , Italy
– name: 11 Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, “Santi Antonio e Biagio e Cesare Arrigo” National Hospital , Alessandria , Italy
– name: 3 Physical and Rehabilitation Medicine, A.S.L. Vercelli , Vercelli , Italy
– name: 1 Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale , Novara , Italy
– name: 4 Rehabilitation Unit, Department of Rehabilitation, “Santi Antonio e Biagio e Cesare Arrigo” National Hospital , Alessandria , Italy
Author_xml – sequence: 1
  givenname: Alessio
  surname: Baricich
  fullname: Baricich, Alessio
  organization: Physical and Rehabilitation Medicine, "Ospedale Maggiore della Carità" University Hospital, Novara, Italy
– sequence: 2
  givenname: Marco
  surname: Battaglia
  fullname: Battaglia, Marco
  organization: Physical and Rehabilitation Medicine, "Ospedale Maggiore della Carità" University Hospital, Novara, Italy
– sequence: 3
  givenname: Daria
  surname: Cuneo
  fullname: Cuneo, Daria
  organization: Physical and Rehabilitation Medicine, A.S.L. Vercelli, Vercelli, Italy
– sequence: 4
  givenname: Lucia
  surname: Cosenza
  fullname: Cosenza, Lucia
  organization: Rehabilitation Unit, Department of Rehabilitation, "Santi Antonio e Biagio e Cesare Arrigo" National Hospital, Alessandria, Italy
– sequence: 5
  givenname: Marzia
  surname: Millevolte
  fullname: Millevolte, Marzia
  organization: Neurorehabilitation Clinic, Department Neurological Sciences, University Hospital of Ancona, Ancona, Italy
– sequence: 6
  givenname: Michela
  surname: Cosma
  fullname: Cosma, Michela
  organization: Neuroscience and Rehabilitation Department, Ferrara University Hospital, Ferrara, Italy
– sequence: 7
  givenname: Mirko
  surname: Filippetti
  fullname: Filippetti, Mirko
  organization: Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 8
  givenname: Stefania
  surname: Dalise
  fullname: Dalise, Stefania
  organization: Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
– sequence: 9
  givenname: Valentina
  surname: Azzollini
  fullname: Azzollini, Valentina
  organization: Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
– sequence: 10
  givenname: Carmelo
  surname: Chisari
  fullname: Chisari, Carmelo
  organization: Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
– sequence: 11
  givenname: Stefania
  surname: Spina
  fullname: Spina, Stefania
  organization: Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy
– sequence: 12
  givenname: Nicoletta
  surname: Cinone
  fullname: Cinone, Nicoletta
  organization: Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy
– sequence: 13
  givenname: Lorenza
  surname: Scotti
  fullname: Scotti, Lorenza
  organization: Department of Translational Medicine, Unit of Medical Statistics, Università del Piemonte Orientale, Novara, Italy
– sequence: 14
  givenname: Marco
  surname: Invernizzi
  fullname: Invernizzi, Marco
  organization: Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, "Santi Antonio e Biagio e Cesare Arrigo" National Hospital, Alessandria, Italy
– sequence: 15
  givenname: Stefano
  surname: Paolucci
  fullname: Paolucci, Stefano
  organization: IRCCS Fondazione Santa Lucia, Rome, Italy
– sequence: 16
  givenname: Alessandro
  surname: Picelli
  fullname: Picelli, Alessandro
  organization: Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 17
  givenname: Andrea
  surname: Santamato
  fullname: Santamato, Andrea
  organization: Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37090974$$D View this record in MEDLINE/PubMed
BookMark eNpVkk1v1DAQhiNUREvpH-CAfOTALv5I7JgLWq34qFSJC5wtx5lsvXLsYDst-3v4o3g_WLW-zOgdz-Px6H1dXfjgoareErxkrJUfBw9zXFJM2ZIQxpjEL6orwnm9oFQ2F0_yy-ompS0uh0nJOHtVXTKBJZaivqr-rp311miHYBhKNDsUBtSFPBd9HlEOf6xHeTcBWqGSTTpb8DmhR5vvUY56HotiUBd1qVq_nePuA0qT9QVpQuzPWohonF22kwOUjIMYkk2f0Mqj0CWIDwUT9k0u-I3Nc38gpJLs3lQvB-0S3JzidfXr65ef6--Lux_fbteru4WpucwLInjLac9b3UhdUwOGN22NKSEdrbmpBee8JQakabjEvGYNJkxLIERQoaFm19XtkdsHvVVTtKOOOxW0VQchxI3SsXzWgRoGLTjA0LWU1riVHUgs-q4TRgzQAhTW5yNrmrsRelN2FrV7Bn1e8fZebcKDIrjMI0RbCO9PhBh-z5CyGm0y4Jz2EOakaIubhgjWsHKVHq-astQUYTi_Q7Dau0Ud3KL2blEnt5Smd08nPLf89wb7B11wwhI
CitedBy_id crossref_primary_10_1016_j_toxicon_2024_107363
crossref_primary_10_3390_toxins16070309
crossref_primary_10_3390_medicina60010023
crossref_primary_10_3390_toxins16040184
Cites_doi 10.1212/WNL.49.1.189
10.1177/15459683211011214
10.1002/acr.20543
10.3390/toxins14090582
10.1161/STROKEAHA.121.034049
10.1007/s00702-013-1145-3
10.2340/16501977-0303
10.1038/sj.sc.3101928
10.1002/mus.20285
10.23736/S1973-9087.17.04796-7
10.1038/sj.sc.3101757
10.1016/j.apmr.2006.12.029
10.1186/s13643-017-0670-9
10.1007/s11940-017-0470-5
10.2147/NDT.S53913
10.3390/toxins7072454
10.1212/WNL.0000000000002560
10.4103/0253-7176.116232
10.1080/10790268.2018.1479053
10.1093/brain/awg036
10.1016/S0003-9993(99)90329-5
10.3390/toxins9090260
10.3390/toxins14090619
10.1007/s12325-009-0082-x
10.1136/practneurol-2011-000155
10.3390/toxins13040236
10.1186/s12883-019-1325-3
10.1152/jappl.1993.75.6.2629
10.1007/s40265-018-1042-z
10.1016/j.pmrj.2017.02.014
10.3390/toxins13120889
10.1007/s00702-015-1384-6
10.1016/j.rehab.2018.08.004
10.3390/toxins14110774
10.1016/j.pmrj.2016.06.016
10.1016/S1474-4422(15)00216-1
10.1186/s13561-022-00374-y
10.3390/toxins12050292
10.1586/14737175.2013.865877
10.1093/ptj/67.2.206
10.1191/1352458504ms1085oa
10.1080/09638280400014576
10.3389/fneur.2022.946500
10.1080/01952307.1987.11719634
ContentType Journal Article
Copyright Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato.
Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato. 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato
Copyright_xml – notice: Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato.
– notice: Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato. 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fneur.2023.1133390
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1664-2295
EndPage 1133390
ExternalDocumentID oai_doaj_org_article_ffa76eefb8224089be907dbb7c7fe8ee
10_3389_fneur_2023_1133390
37090974
Genre Journal Article
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
E3Z
EMOBN
F5P
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c469t-176862d68a59a42cec65840211b246c4766681ce9c56906435013a9e11727ae43
IEDL.DBID RPM
ISSN 1664-2295
IngestDate Tue Oct 22 15:16:13 EDT 2024
Tue Sep 17 21:30:53 EDT 2024
Sat Oct 05 06:27:23 EDT 2024
Thu Sep 26 17:10:08 EDT 2024
Sat Sep 28 08:19:10 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords botulinum toxin
spinal cord injury
pain
rehabilitation
multiple sclerosis
traumatic brain injury
spasticity
movement disorders
Language English
License Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c469t-176862d68a59a42cec65840211b246c4766681ce9c56906435013a9e11727ae43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Laura Mori, University of Genoa, Italy; Philippe Picaut, Algo Therapeutix, France
This article was submitted to Neurorehabilitation, a section of the journal Frontiers in Neurology
Edited by: Luigi Tesio, University of Milan, Italy
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117778/
PMID 37090974
PQID 2805517353
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_ffa76eefb8224089be907dbb7c7fe8ee
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10117778
proquest_miscellaneous_2805517353
crossref_primary_10_3389_fneur_2023_1133390
pubmed_primary_37090974
PublicationCentury 2000
PublicationDate 2023-04-06
PublicationDateYYYYMMDD 2023-04-06
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-06
  day: 06
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in neurology
PublicationTitleAlternate Front Neurol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Esquenazi (B3) 2017; 9
Simpson (B12) 2016; 86
Baricich (B31) 1996; 122
Park (B41) 2017; 9
Palazón-García (B37) 2019; 42
Datta Gupta (B47) 2019; 19
Simpson (B4) 2017; 9
Sköld (B24) 1999; 80
Baccouche (B49) 2022; 14
Battaglia (B15) 2021; 13
Charan (B35) 2013; 35
Gupta (B48) 2018; 7
Marten (B33) 2022; 12
Jacinto (B50) 2022; 13
Wissel (B13) 2009; 41
Barolat (B23) 1987; 10
B38
Tan (B44) 2021; 52
Meseguer-Henarejos (B30) 2018; 54
Pandyan (B2) 2005; 27
Pozzilli (B18) 2013; 13
Dos Santos (B9) 2021; 9
Bohannon (B29) 1987; 67
Roncoroni (B46) 2020; 12
Crone (B7) 2003; 126
Novarella (B51) 2022; 14
Sloop (B34) 1997; 49
Franceschini (B16) 2014; 50
Adams (B36) 2005; 43
B42
Schramm (B39) 1996; 121
Kepczyńska (B43) 2022; 14
Maynard (B26) 1990; 71
Intiso (B45) 2015; 7
Gioux (B6) 1993; 75
Martin (B21) 2014; 10
Safarpour (B22) 2017; 19
Santamato (B14) 2019; 79
Picelli (B11) 2019; 62
Kheder (B8) 2012; 12
Biering-Sørensen (B28) 2006; 44
Li (B1) 2021; 35
Mahoney (B25) 2007; 88
Baricich (B17) 2021; 13
Smania (B10) 2010; 46
Gracies (B40) 2015; 14
Rizzo (B19) 2004; 10
Zwibel (B20) 2009; 26
Bose (B27) 2015
Hawker (B32) 2011; 63
Gracies (B5) 2005; 31
References_xml – volume: 49
  start-page: 189
  year: 1997
  ident: B34
  article-title: Human response to botulinum toxin injection: type B compared with type A
  publication-title: Neurology.
  doi: 10.1212/WNL.49.1.189
  contributor:
    fullname: Sloop
– volume: 35
  start-page: 601
  year: 2021
  ident: B1
  article-title: A new definition of poststroke spasticity and the interference of spasticity with motor recovery from acute to chronic stages
  publication-title: Neurorehabil Neural Repair.
  doi: 10.1177/15459683211011214
  contributor:
    fullname: Li
– volume: 63
  start-page: S240
  year: 2011
  ident: B32
  article-title: Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), MCGILL pain questionnaire (MPQ), short-form MCGILL pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (sf-36 bps), and measure of intermittent and constant osteoarthritis pain (ICOAP)
  publication-title: Arthritis Care Res.
  doi: 10.1002/acr.20543
  contributor:
    fullname: Hawker
– volume: 50
  start-page: 525
  year: 2014
  ident: B16
  article-title: Italian Spasticity Study Group. Management of stroke patients submitted to botulinum toxin type A therapy: a Delphi survey of an Italian expert panel of specialist injectors
  publication-title: Eur J Phys Rehabil Med.
  contributor:
    fullname: Franceschini
– volume: 14
  start-page: 582
  year: 2022
  ident: B49
  article-title: Goal-setting in multiple sclerosis-related spasticity treated with botulinum toxin: the GASEPTOX study
  publication-title: Toxins.
  doi: 10.3390/toxins14090582
  contributor:
    fullname: Baccouche
– volume: 52
  start-page: 3759
  year: 2021
  ident: B44
  article-title: Ultrasound-Guided BoNT-A (Botulinum Toxin A) injection into the subscapularis for hemiplegic shoulder pain: a randomized, double-blind, placebo-controlled trial
  publication-title: Stroke.
  doi: 10.1161/STROKEAHA.121.034049
  contributor:
    fullname: Tan
– volume: 121
  start-page: 521
  year: 1996
  ident: B39
  article-title: Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry
  publication-title: J Neural Transm Vienna Austria
  doi: 10.1007/s00702-013-1145-3
  contributor:
    fullname: Schramm
– volume: 41
  start-page: 13
  year: 2009
  ident: B13
  article-title: European consensus table on the use of botulinum toxin type A in adult spasticity
  publication-title: J Rehabil Med.
  doi: 10.2340/16501977-0303
  contributor:
    fullname: Wissel
– volume: 44
  start-page: 708
  year: 2006
  ident: B28
  article-title: Spasticity-assessment: a review
  publication-title: Spinal Cord.
  doi: 10.1038/sj.sc.3101928
  contributor:
    fullname: Biering-Sørensen
– volume: 31
  start-page: 552
  year: 2005
  ident: B5
  article-title: Pathophysiology of spastic paresis. II: Emergence of muscle overactivity
  publication-title: Muscle Nerve.
  doi: 10.1002/mus.20285
  contributor:
    fullname: Gracies
– volume: 54
  start-page: 576
  year: 2018
  ident: B30
  article-title: Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis
  publication-title: Eur J Phys Rehabil Med.
  doi: 10.23736/S1973-9087.17.04796-7
  contributor:
    fullname: Meseguer-Henarejos
– volume: 43
  start-page: 577
  year: 2005
  ident: B36
  article-title: Spasticity after spinal cord injury
  publication-title: Spinal Cord.
  doi: 10.1038/sj.sc.3101757
  contributor:
    fullname: Adams
– volume: 88
  start-page: 287
  year: 2007
  ident: B25
  article-title: Spasticity experience domains in persons with spinal cord injury
  publication-title: Arch Phys Med Rehabil.
  doi: 10.1016/j.apmr.2006.12.029
  contributor:
    fullname: Mahoney
– volume: 7
  start-page: 1
  year: 2018
  ident: B48
  article-title: A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity
  publication-title: Syst Rev.
  doi: 10.1186/s13643-017-0670-9
  contributor:
    fullname: Gupta
– volume: 19
  start-page: 33
  year: 2017
  ident: B22
  article-title: Botulinum toxin treatment in multiple sclerosis-a review
  publication-title: Curr Treat Options Neurol.
  doi: 10.1007/s11940-017-0470-5
  contributor:
    fullname: Safarpour
– volume: 10
  start-page: 111
  year: 2014
  ident: B21
  article-title: Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review
  publication-title: Neuropsychiatr Dis Treat.
  doi: 10.2147/NDT.S53913
  contributor:
    fullname: Martin
– volume: 7
  start-page: 2454
  year: 2015
  ident: B45
  article-title: Botulinum toxin type a for the treatment of neuropathic pain in neuro-rehabilitation
  publication-title: Toxins.
  doi: 10.3390/toxins7072454
  contributor:
    fullname: Intiso
– volume: 86
  start-page: 1818
  year: 2016
  ident: B12
  article-title: Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American academy of neurology
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000002560
  contributor:
    fullname: Simpson
– volume: 35
  start-page: 121
  year: 2013
  ident: B35
  article-title: How to calculate sample size for different study designs in medical research?
  publication-title: Indian J Psychol Med.
  doi: 10.4103/0253-7176.116232
  contributor:
    fullname: Charan
– volume: 42
  start-page: 281
  year: 2019
  ident: B37
  article-title: Esclarin-de Ruz A, Benavente-Valdepeñas AM. Treatment of spasticity in spinal cord injury with botulinum toxin
  publication-title: J Spinal Cord Med.
  doi: 10.1080/10790268.2018.1479053
  contributor:
    fullname: Palazón-García
– volume: 126
  start-page: 495
  year: 2003
  ident: B7
  article-title: Appearance of reciprocal facilitation of ankle extensors from ankle flexors in patients with stroke or spinal cord injury
  publication-title: Brain J Neurol.
  doi: 10.1093/brain/awg036
  contributor:
    fullname: Crone
– ident: B38
– volume: 9
  start-page: 1
  year: 2021
  ident: B9
  article-title: Use of the international classification of functioning, disability and health (ICF) to expand and standardize the assessment of quality-of-life following a stroke: proposal for the use of codes and qualifiers
  publication-title: Disabil Rehabil.
  contributor:
    fullname: Dos Santos
– volume: 80
  start-page: 1548
  year: 1999
  ident: B24
  article-title: Spasticity after traumatic spinal cord injury: nature, severity, and location
  publication-title: Arch Phys Med Rehabil.
  doi: 10.1016/S0003-9993(99)90329-5
  contributor:
    fullname: Sköld
– volume: 9
  start-page: E260
  year: 2017
  ident: B41
  article-title: Botulinum Toxin for the treatment of neuropathic pain
  publication-title: Toxins.
  doi: 10.3390/toxins9090260
  contributor:
    fullname: Park
– volume: 14
  start-page: 619
  year: 2022
  ident: B43
  article-title: Botulinum toxin—a current place in the treatment of chronic migraine and other primary headaches
  publication-title: Toxins.
  doi: 10.3390/toxins14090619
  contributor:
    fullname: Kepczyńska
– volume: 71
  start-page: 566
  year: 1990
  ident: B26
  article-title: Epidemiology of spasticity following traumatic spinal cord injury
  publication-title: Arch Phys Med Rehabil.
  contributor:
    fullname: Maynard
– volume: 26
  start-page: 1043
  year: 2009
  ident: B20
  article-title: Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis
  publication-title: Adv Ther.
  doi: 10.1007/s12325-009-0082-x
  contributor:
    fullname: Zwibel
– volume: 12
  start-page: 289
  year: 2012
  ident: B8
  article-title: Spasticity: pathophysiology, evaluation and management
  publication-title: Pract Neurol.
  doi: 10.1136/practneurol-2011-000155
  contributor:
    fullname: Kheder
– volume: 13
  start-page: 236
  year: 2021
  ident: B17
  article-title: BoNT-A for post-stroke spasticity: guidance on unmet clinical needs from a delphi panel approach
  publication-title: Toxins.
  doi: 10.3390/toxins13040236
  contributor:
    fullname: Baricich
– volume: 46
  start-page: 423
  year: 2010
  ident: B10
  article-title: Rehabilitation procedures in the management of spasticity
  publication-title: Eur J Phys Rehabil Med.
  contributor:
    fullname: Smania
– volume: 19
  start-page: 96
  year: 2019
  ident: B47
  article-title: Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticity - a randomized double-blind placebo controlled study
  publication-title: BMC Neurol.
  doi: 10.1186/s12883-019-1325-3
  contributor:
    fullname: Datta Gupta
– volume: 75
  start-page: 2629
  year: 1993
  ident: B6
  article-title: Effects of immobilizing the cat peroneus longus muscle on the activity of its own spindles
  publication-title: J Appl Physiol Bethesda Md.
  doi: 10.1152/jappl.1993.75.6.2629
  contributor:
    fullname: Gioux
– volume: 79
  start-page: 143
  year: 2019
  ident: B14
  article-title: Botulinum toxin type A for the treatment of lower limb spasticity after stroke
  publication-title: Drugs.
  doi: 10.1007/s40265-018-1042-z
  contributor:
    fullname: Santamato
– volume: 9
  start-page: 960
  year: 2017
  ident: B3
  article-title: OnabotulinumtoxinA for lower limb spasticity: guidance from a delphi panel approach
  publication-title: PM R.
  doi: 10.1016/j.pmrj.2017.02.014
  contributor:
    fullname: Esquenazi
– volume: 13
  start-page: 889
  year: 2021
  ident: B15
  article-title: Triceps surae muscle characteristics in spastic hemiparetic stroke survivors treated with botulinum toxin type a: clinical implications from ultrasonographic evaluation
  publication-title: Toxins.
  doi: 10.3390/toxins13120889
  contributor:
    fullname: Battaglia
– volume: 122
  start-page: 1283
  year: 1996
  ident: B31
  article-title: High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis
  publication-title: J Neural Transm Vienna Austria.
  doi: 10.1007/s00702-015-1384-6
  contributor:
    fullname: Baricich
– volume: 62
  start-page: 291
  year: 2019
  ident: B11
  article-title: Adjuvant treatments associated with botulinum toxin injection for managing spasticity: an overview of the literature
  publication-title: Ann Phys Rehabil Med.
  doi: 10.1016/j.rehab.2018.08.004
  contributor:
    fullname: Picelli
– volume: 14
  start-page: 774
  year: 2022
  ident: B51
  article-title: Persistence with botulinum toxin treatment for spasticity symptoms in multiple sclerosis
  publication-title: Toxins.
  doi: 10.3390/toxins14110774
  contributor:
    fullname: Novarella
– volume: 9
  start-page: 136
  year: 2017
  ident: B4
  article-title: OnabotulinumtoxinA injection for poststroke upper-limb spasticity: guidance for early injectors from a delphi panel process
  publication-title: PM R.
  doi: 10.1016/j.pmrj.2016.06.016
  contributor:
    fullname: Simpson
– volume: 14
  start-page: 992
  year: 2015
  ident: B40
  article-title: Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(15)00216-1
  contributor:
    fullname: Gracies
– ident: B42
– volume: 12
  start-page: 28
  year: 2022
  ident: B33
  article-title: Feasibility properties of the EQ-5D-3L and 5L in the general population: evidence from the GP patient survey on the impact of age
  publication-title: Health Econ Rev.
  doi: 10.1186/s13561-022-00374-y
  contributor:
    fullname: Marten
– volume: 12
  start-page: 292
  year: 2020
  ident: B46
  article-title: Health-related quality of life outcomes from botulinum toxin treatment in spasticity
  publication-title: Toxins.
  doi: 10.3390/toxins12050292
  contributor:
    fullname: Roncoroni
– volume: 13
  start-page: 49
  year: 2013
  ident: B18
  article-title: Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice
  publication-title: Expert Rev Neurother.
  doi: 10.1586/14737175.2013.865877
  contributor:
    fullname: Pozzilli
– year: 2015
  ident: B27
  article-title: Traumatic Brain Injury (TBI)-Induced Spasticity: Neurobiology, Treatment, and Rehabilitation
  publication-title: Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects
  contributor:
    fullname: Bose
– volume: 67
  start-page: 206
  year: 1987
  ident: B29
  article-title: Interrater reliability of a modified ashworth scale of muscle spasticity
  publication-title: Phys Ther.
  doi: 10.1093/ptj/67.2.206
  contributor:
    fullname: Bohannon
– volume: 10
  start-page: 589
  year: 2004
  ident: B19
  article-title: Prevalence and treatment of spasticity reported by multiple sclerosis patients
  publication-title: Mult Scler Houndmills Basingstoke Engl.
  doi: 10.1191/1352458504ms1085oa
  contributor:
    fullname: Rizzo
– volume: 27
  start-page: 2
  year: 2005
  ident: B2
  article-title: Spasticity: clinical perceptions, neurological realities and meaningful measurement
  publication-title: Disabil Rehabil.
  doi: 10.1080/09638280400014576
  contributor:
    fullname: Pandyan
– volume: 13
  start-page: 946500
  year: 2022
  ident: B50
  article-title: Experiences of patients with poststroke spasticity throughout a botulinum toxin treatment cycle: results from a prospective ethnographic study
  publication-title: Front Neurol.
  doi: 10.3389/fneur.2022.946500
  contributor:
    fullname: Jacinto
– volume: 10
  start-page: 35
  year: 1987
  ident: B23
  article-title: Spasms in spinal cord injury: a study of 72 subjects
  publication-title: J Am Paraplegia Soc.
  doi: 10.1080/01952307.1987.11719634
  contributor:
    fullname: Barolat
SSID ssj0000399363
Score 2.3918417
Snippet Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1133390
SubjectTerms botulinum toxin
movement disorders
multiple sclerosis
Neurology
pain
spasticity
spinal cord injury
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4psArQaJG4QmsRPbvW0RVYVUTlTqzbIdWywqSdUkEvwe_igzTna1i5C4cIucL8dvbM-zJ28Ye9N63ypbcPTcrMxFy22uoo25qHwlPBpQY-l_54vPzfml-HRVX-2k-qKYsFkeeG644xitbEKILoU7Ku0C0rnWOellDCqENPoWeodMpTGY5t2Gz3_JIAvTx5H0Id9TsnBKY8I5DcI7M1ES7P-bl_lnsOTO7HP2gN1f3EZYzdV9yO6E7hG7e7FsjD9mvxZ9z2sIpAlh_U_oI7h-pEDz6TuM_Y91B7TeCivAo0VOdQBahwV845SkW8FRxgi84Bs29TsYbihnFhBB3Zb1t7AJQoQB64Lfth5OYNVB77YrvHjTdU-ZkKY2PSGJ2D5hl2cfv3w4z5f8C7lH0jySdiTynbZRttYWwQue3BV0CkpXicYLidRHlT5oX5PcsaA9Sm51KMkpskHwp-yg67vwnEFZWtkKJawqovCysqJtpNaxkYV1unYZe7vBwtzMMhsG6QkhZxJyhpAzC3IZOyW4tleSRHYqQMMxi-GYfxlOxl5vwDbYpWifxHahnwZTqQL9SMlrnrFnM_jbV3FZ6AI5WMbUnlns1WX_TLf-mmS7S5Lfk1K9-B-1f8nuUYukGKLmFTsYb6dwiO7R6I5ST_gNBXkUYw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwGA3rCuKLeLfrhQi-adde0lwEkVFcFmF9cmDfQpIm7sjY7k5b2P09_lG_L5MZHFnBt9Jb0p6k-U7y9RxCXrXOtdIUNURuRuSsrU0ugwk5q1zFHDQgbvB_55Ov_HjOvpw2p3tkY3eUXuBwLbVDP6n5anl4eXH1ATr8e2ScMN6-DSj9eIg-4OhQUgOLv0FuVgyYOqbypXA_fplxNI7maiXnLEcn6_V_NP-4zc5YFSX9r4tD_06n_GN8OrpL7qTAks7WLeEe2fPdfXLrJC2dPyC_kgLoknpUjTDuivaB2n7EVPTpJx37y0VHcUaWzihsJcHVgeJMLYUSpyjuSi16SsAJPwCMN3Q4R1ctihR2u69f0U2aIh2gLvBsi-EdnXW0t9s5YLho2aNX0tTGO0SZ24dkfvT526fjPDk05A5o9YjqksCIWi5NowzA6x0GNBA2lLZi3DEB5EiWzivXoCAyw1XM2ihfYthkPKsfkf2u7_wTQsvSiJZJZmQRmBOVYS0XSgUuCmNVYzPyeoOFPl8LcWggMIicjshpRE4n5DLyEeHanoki2nFHv_quU5_UIRjBvQ82ZtJKZb0qRGutcCJ46X1GXm7A1tDpcCXFdL6fBl3JAiJNUTd1Rh6vwd8WVYtCFcDSMiJ3msVOXXaPdIuzKOxdokCfEPLgPwp-Sm7jA8ckIv6M7I-ryT-H-Gi0L2Kj_w2_1xGw
  priority: 102
  providerName: Scholars Portal
Title Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study
URI https://www.ncbi.nlm.nih.gov/pubmed/37090974
https://search.proquest.com/docview/2805517353
https://pubmed.ncbi.nlm.nih.gov/PMC10117778
https://doaj.org/article/ffa76eefb8224089be907dbb7c7fe8ee
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZ294C4IN6EhZWRuEHaJHb94FZWrFZIRRxYaW-R7dhQ1CZVk0js7-GPMuMmVYs4cYmixI4df2N7xh5_Q8jbyrlKmYyB5mZkyitmUhVMSHnhCu5AgITB886LL-L6hn--nd2eEDGehYlO-84uJ_VqPamXP6Jv5WbtpqOf2PTr4jJHIjMp1fSUnIKEHtjocfzFOVew3QkZsMD0NCA35AQDhWMIE8ZwAD6YhSJZ_780zL8dJQ9mnquH5MGgMtL5rmqPyImvH5N7i2FT_An5PXB7rqhHPgjj7mgTqG06dDLv17Rrfi1rimutdE7hbqBSbSmuwVIosY-0rdRitAhI8BOa-T1tNxgvi6Jxun_WbOnogEhbqAv827L9QOc1bex-dRcyrRqMgtRX8QuRwPYpubn69O3yOh1iL6QODOYOeSPB1qmEMjNtADjvUFUBhSC3BReOSzB7VO68djOkOua4P8mM9jkqRMZz9oyc1U3tXxCa50ZWXHGjssCdLAyvhNQ6CJkZq2c2Ie9GLMrNjmKjBNMEkSsjciUiVw7IJeQjwrVPifTY8UGz_V4OQlKGYKTwPtjoI6u09TqTlbXSyeCV9wl5M4JdQnfCPRJT-6Zvy0JloENKNmMJeb4Df18Uk5nOwP5KiDoSi6O6HL8BCY6U3aPEvvz_rOfkPrZD9BoSr8hZt-39a1CIOnsRFxLguuDqIvaFPyLGEys
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGkICXcR0LVyPxBk1zcWyHtzIxFVgnHjaxt8h2HCi0SdUkEvB3-KOc4yRVO_ECb5ETJ4792T7H_vwdQl7mxuRSBTFYbkqMWB6rkSxUMWKRiZgBAHGF551nZ3x6wT5cJpd7hA9nYRxp3-i5Xy6Wfjn_6riVq6UZDzyx8afZcYhCZkLI8TVyHTpswLa8dDcC46zL4-6MDPhg6bhAdUgfQ4VjEJM4xiF4ax5ycv1_szGvUiW35p6T2-TzUOqOcvLdbxvtm19XBB3__bfukIPeHKWT7v5dsmfLe-TGrN9wv09-97qhC2pRa0KZn7QqqK4aJLC3S9pUP-YlxXVcOqFw1cu01hTXdyn8S-skYanGSBTwwDdowte0XmEsLoqO7yatWtOB3EhrKAvU2rx-QyclrfRm5RgyLSqMsNTm7g1OHPcBuTh5d348HfVxHUYGnPEGNSnBj8q5VEmqABTWoBkExkaoI8YNE-BSydDY1CQoo8xw7zNWqQ3R2FKWxYdkv6xKe0RoGCqRM8mUDApmRKRYzkWaFlwESqeJ9siroZWzVSffkYHbg5jIHCYyxETWY8IjbxEImydRetslVOsvWd9SWVEowa0ttOPfylTbNBC51sKIwkprPfJigFEGXRX3X1Rpq7bOIhmAfSriJPbIww5Wm0_FIkgD8O08IncAt1OW3TsAIycHPsDm0f9nfU5uTs9np9np-7OPj8ktrBPHTuJPyH6zbu1TMLwa_cz1sj9SkzOD
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVgkEZseD_C00jsIM3LiR12ZaAaHh3NgpFGYhHZjg2FNqmaRAJ-hx_lXiep2hGr2UWOnTjxsX2vfXwuIS9LrUshwwQsN8l9VibSF1Zan8U6ZhoAlEk87zw_yY7P2Mfz9HxgVTYDrbLSajGplqtJtfjuuJXrlQ5GnlhwOj-KUMiMcxGsSxtcJdeg04bZjqfuRmGcebOkPycDflgeWFSInGC4cAxkkiQ4DO_MRU6y_3925kW65M78M7tJvo4172knPyddqyb6zwVRx8t92i1yYzBL6bTPc5tcMdUdcjgfNt7vkr-DfuiSGtSckPo3rS1VdYtE9m5F2_rXoqK4nkunFK4GudaG4jovhe_pnDQsVRiRAjL8gKZ8TZs1xuSi6ABv0-oNHUmOtIG6wJ9bNG_otKK12q4gQ6FljZGWutI9wYnk3iNns_dfjo79Ib6Dr8Epb1GbEvypMhMyzSWAw2g0h8DoiFTMMs04uFYi0ibXKcopM9wDTWRuIjS6pGHJfXJQ1ZV5SGgUSV4ywaQILdM8lqzMeJ7bjIdS5anyyKuxpYt1L-NRgPuDuCgcLgrERTHgwiNvEQzbnCjB7RLqzbdiaK3CWskzY6xyPFyRK5OHvFSKa26NMMYjL0YoFdBlcR9GVqbumiIWIdipPEkTjzzoobV9VcLDPAQfzyNiD3R7ddm_A1BysuAjdB5dvuhzcnj6blZ8_nDy6TG5jr_EkZSyJ-Sg3XTmKdhfrXrmOto_wAg2Aw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+efficacy+of+botulinum+toxin+type+A+in+patients+with+traumatic+brain+injury%2C+spinal+cord+injury%2C+or+multiple+sclerosis%3A+An+observational+longitudinal+study&rft.jtitle=Frontiers+in+neurology&rft.au=Baricich%2C+Alessio&rft.au=Battaglia%2C+Marco&rft.au=Cuneo%2C+Daria&rft.au=Cosenza%2C+Lucia&rft.date=2023-04-06&rft.issn=1664-2295&rft.eissn=1664-2295&rft.volume=14&rft.spage=1133390&rft.epage=1133390&rft_id=info:doi/10.3389%2Ffneur.2023.1133390&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2295&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2295&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2295&client=summon